NextCure (NASDAQ:NXTC) Stock Price Down 3.7% – What’s Next?

NextCure, Inc. (NASDAQ:NXTC) traded down 3.7% on Monday . The company traded as low as $12.16 and last traded at $13.22. 88,662 shares were traded during mid-day trading, an increase of 181% from the average session volume of 31,518 shares. The stock had previously closed at $13.73.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. LADENBURG THALM/SH SH raised NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a research note on Wednesday, January 28th. Finally, Wall Street Zen raised NextCure to a “hold” rating in a research report on Saturday, December 13th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, NextCure currently has an average rating of “Moderate Buy” and an average price target of $23.00.

NextCure Trading Down 3.7%

The firm has a market cap of $46.40 million, a P/E ratio of -0.55 and a beta of 1.54. The business’s fifty day simple moving average is $12.55 and its 200-day simple moving average is $9.64.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new stake in shares of NextCure during the fourth quarter valued at about $160,000. Millennium Management LLC bought a new stake in NextCure during the 4th quarter worth approximately $185,000. Geode Capital Management LLC increased its holdings in NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares during the period. Cable Car Capital LP lifted its stake in NextCure by 13.1% in the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after purchasing an additional 88,040 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after purchasing an additional 5,300 shares during the period. Institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.